Pro Dex Inc (NASDAQ: PDEX)

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000788920
Market Cap 128.91 Mn
P/B 3.10
P/E 11.37
P/S 1.79
ROIC (Qtr) 15.73
Div Yield % 0.00
Rev 1y % (Qtr) 11.14
Total Debt (Qtr) 10.89 Mn
Debt/Equity (Qtr) 0.26

About

Pro-Dex, Inc., also recognized by its stock symbol PDEX, operates in the design, development, and manufacture of autoclavable, battery-powered, and electric, multi-function surgical drivers and shavers. The company's primary focus lies within the orthopedic, thoracic, and craniomaxillofacial markets. Pro-Dex boasts patented adaptive torque-limiting technology and proprietary sealing solutions that appeal to its main customer base of medical device distributors. Additionally, the company produces and sells rotary air motors to a diverse range of...

Read more

Price action

Investment thesis

Bull case

  • Strong operating cash flow of 6.46M provides robust 0.59x coverage of total debt 10.89M, indicating excellent debt servicing capability and financial flexibility.
  • Healthy cash reserves of 7.95M provide 3.22x coverage of short-term debt 2.47M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 62.24M provides 5.71x coverage of total debt 10.89M, indicating robust asset backing and low credit risk.
  • Operating cash flow of 6.46M provides strong 10.15x coverage of stock compensation 637000, indicating sustainable incentive practices.
  • Tangible assets of 62.24M provide exceptional 381.87x coverage of deferred revenue 163000, showing strong service capability backing.

Bear case

  • Operating cash flow of 6.46M barely covers its investment activities of 9.51M, with a coverage ratio of 0.68, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Cash reserves of 7.95M provide limited coverage of acquisition spending of (899000), which is -8.85x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • Operating cash flow of 6.46M provides minimal 1.63x coverage of tax expenses of 3.96M, suggesting potential tax planning inefficiencies or unsustainable tax positions.
  • Free cash flow of 6.02M represents just -1.02x of debt issuance (5.92M), suggesting concerning reliance on leverage rather than internal cash generation for growth.
  • Operating cash flow of 6.46M is outpaced by equity issuance of (2.47M) (-2.62 ratio), indicating concerning reliance on equity markets for funding operations.

Customer Breakdown of Revenue (2025)

Customer Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 174.27 Bn 61.02 17.31 0.00 Bn
2 BDX Becton Dickinson & Co 59.72 Bn 37.77 3.14 19.18 Bn
3 RMD Resmed Inc 39.76 Bn 26.76 7.37 0.85 Bn
4 ALC Alcon Inc 38.93 Bn 37.18 3.82 5.24 Bn
5 WST West Pharmaceutical Services Inc 17.69 Bn 133.13 12.54 0.30 Bn
6 HOLX Hologic Inc 16.81 Bn 30.91 4.07 2.52 Bn
7 COO Cooper Companies, Inc. 16.37 Bn 43.67 4.00 2.51 Bn
8 ALGN Align Technology Inc 13.73 Bn 36.29 3.45 0.09 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 2.28 2.75
EV to Cash from Ops. EV/CFO 22.00 39.87
EV to Debt EV to Debt 13.05 27.09
EV to EBIT EV/EBIT 8.82 32.86
EV to EBITDA EV/EBITDA 11.28 19.31
EV to Free Cash Flow [EV/FCF] EV/FCF 23.61 0.88
EV to Market Cap EV to Market Cap 1.10 -4.26
EV to Revenue EV/Rev 1.97 252.61
Price to Book Value [P/B] P/B 3.10 6.13
Price to Earnings [P/E] P/E 11.37 184.03
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -1.09
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.36
Dividend per Basic Share Div per Share (Qtr) 0.00 0.25
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 8.74
Interest Coverage Int. cover (Qtr) 19.80 -117.83
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 63.16 -53.47
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 11,950.00 414.02
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -1.48
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 64.86 -57.42
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 9.80 -106.89
EBIT Growth (1y) % EBIT 1y % (Qtr) 71.62 -37.00
EBT Growth (1y) % EBT 1y % (Qtr) 74.93 -42.63
EPS Growth (1y) % EPS 1y % (Qtr) 70.10 -15.05
FCF Growth (1y) % FCF 1y % (Qtr) 262.33 56.29
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 11.39 67.95
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 1.16 0.54
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.03
Cash Ratio Cash Ratio (Qtr) 0.65 2.51
Current Ratio Curr Ratio (Qtr) 4.03 7.80
Debt to Equity Ratio Debt/Equity (Qtr) 0.26 0.55
Interest Cover Ratio Int Coverage (Qtr) 19.80 -117.83
Times Interest Earned Times Interest Earned (Qtr) 19.80 -117.83
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 24.10 -2,368.59
EBIT Margin % EBIT Margin % (Qtr) 22.35 -2,472.59
EBT Margin % EBT Margin % (Qtr) 21.22 -2,442.52
Gross Margin % Gross Margin % (Qtr) 28.30 30.06
Net Profit Margin % Net Margin % (Qtr) 15.70 -2,438.49